ClinicalTrials.gg
CompletedNCT01222949Updated Oct 18, 2010

A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™

A Phase 1 interventional study of Eurartesim in Malaria, Falciparum, sponsored by sigma-tau i.f.r. S.p.A.. Completed at 2 sites in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-10-18.

Sponsored by sigma-tau i.f.r. S.p.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing artenimol in Malaria, Falciparum — 1 open to participants now, 3 under way, 1 of them phase 3. artenimol · Malaria, Falciparum.

Enrollment
22nd of 23
80 · median 663
Started
2010
with 3 others
Phase 1
3 of 23
none open now
Registered
3rd of 23
by date
Lead sponsor
3 of 23
sigma-tau i.f.r. S.p.A.

Among the 23 studies testing artenimol in Malaria, Falciparum, this one is the 22nd largest by enrollment, is one of 4 that started in 2010, is one of 3 in phase 1, and was the 3rd registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

1 of the 23 studies testing artenimol in Malaria, Falciparum is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About artenimol

artenimol: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing artenimol in Malaria, Falciparum, or all of them as a file.
02

Study summary

The Study was designed to evaluate the pharmacokinetics of DHA and PQ in healthy volunteers and to assess the effect of ethnicity (Asian vs Caucasian), gender and body weight on the relative bioavailability of DHA and PQ.

03

Conditions studied

  • Malaria, Falciparum

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caucasian or Asian healthy subjects, Male or female, aged between 18 and 50 years (inclusive)
  • (BMI) between 19.0 kg/m2 and 27.0 kg/m2 inclusive, with a minimum body weight of 36 kg.
  • Agreed to use two approved methods of
  • Had given written to participate in this study in accordance with local regulations

Exclusion criteria

Exclusion Criteria:

  • Had received or was anticipated to receive a prescription medication within 14 days prior to the start of dosing
  • Pregnant or lactating (females only)
  • Abnormal laboratory test results deemed at screening
  • Positive urine drug test or alcohol breath test
  • Acute therapy for a serious infection within 30 days of study entry
  • History of significant drug allergies or significant allergic reactions
  • Had participated in a clinical trial or had received an experimental therapy within 30 days or 10 half-lives of the drug
  • Receipt of blood or blood products, or loss or donation of 450 mL or more of blood within 90 days before the first dose administration
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Asian Healthy Volunteers

    Asian males with a body weight ≤ 65 kg (12 subjects) Asian females with a body weight ≤ 65 kg (12 subjects)

    Drug: Eurartesim

  • Experimental
    Caucasian Healthy Volunteers

    Caucasian males with a body weight ≤ 65 kg (12 subjects) Caucasian females with a body weight ≤ 65 kg (12 subjects) Caucasian males with a body weight \> 65 kg (24 subjects)

    Drug: Eurartesim

Interventions

  • DrugEurartesim

    Drug pages: Artenimol · Piperaquine

    Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.

06

What researchers measure

Primary outcomes

  1. PK: tmax, Cmax, AUC0-12(DHA), AUC0-24(PQ), AUC0-inf, λz, t1/2

    DHA evaluation: At pre-dose on day Day 0 and Day 2 and then at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours post-dose. PQ evaluation: At pre-dose Day 0 and then at 1, 2, 3, 4, 5, 6, 8, 12, and 16 hours post-dose; then at pre-dose Day 1 and Day 2 and finally at 1, 2, 3, 4, 5, 6, 8, 12, and 16 hours post-dose on day 2; on Day 3, 4, 5, 7, 14, 21, 28, 42, 56 and 90.

    Time frame: During the first and last day of drug administration (day 0 and 2) and followed up till Day 90

Secondary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs)

    Number of TEAEs and number of Subjects experiencing Adverse Events during all the study period

    Time frame: From Day 0 till Day 90

  2. Hematology and blood chemistry changes respect to baseline values

    Abnormalities in hematology (Haemoglobin, Hematocrit,RBC count, White cell count and differential count, Platelets) and clinical chemistry (Protein, Sodium, Potassium, Chloride ,Total Bilirubin, Conjugated Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Total Cholesterol, Glucose, Bicarbonate, Urea, Urate, Lactate Dehydrogenase, Albumin, Globulins, Triglycerides, Creatinine, Alkaline Phosphatase, Gamma glutamyltransferase, Total Calcium, Phosphate, C-reactive protein) will be recorded the day of the last study drug intake and after 30 days from the start of the drug treatment

    Time frame: Day 0, Day 3, Day 28, Day 90

  3. QTc interval prolongation

    ECG recordings will be obtained at baseline, after the last drug intake and 30 days follow-up to investigate changes in ECG parameters, and specifically QTc interval changes respect to baseline

    Time frame: Day 0, day 3, day 28, day 90

07

Study locations

2 sites
  • CMAX, a division of IDT Australia Limited
    Adelaide, SA 5000, Australia
  • Nucleus Network Limited
    Melbourne, VIC 3004, Australia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Jul 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2010
First posted
Oct 18, 2010
Start
Feb 2010
Primary completionActual
Jul 2010
CompletionActual
Aug 2010
Last update
Oct 18, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01222949
Lead sponsor
sigma-tau i.f.r. S.p.A.
Collaborators
CPR Pharma Services Pty Ltd, Australia
First posted
Oct 18, 2010
Start date
Feb 2010
Primary completion
Jul 2010
Completion
Aug 2010
Last update
Oct 18, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Artenimol · Piperaquine

Start the discussion